Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: JanOne announces an improved formulation of JAN101
Jun 07, 2022: JanOne announces the issuance of U.S. patent covering a method of improving nerve function using JAN101
May 10, 2022: Hemostemix announces its intellectual property is back home
Jul 22, 2021: JanOne selects CPC Clinical Research as trial mager for phase 2b study of JAN101 for peripheral artery disease patients
Feb 10, 2021: Sanifit granted orphan drug desigtion by the FDA for SNF472 for the treatment of peripheral arterial disease in patients with end-stage kidney disease
Aug 26, 2020: JanOne advances its potential peripheral artery disease and Covid-19 vascular inflammation treatment towards trial readiness
Aug 21, 2020: JanOne to host telebriefing to discuss drug candidate JAN101 for treatment of peripheral artery disease (PAD) and potential applications for COVID-19 vascular complications
Aug 19, 2020: JanOne to present at The LD 500 Virtual Conference
Aug 11, 2020: JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials
Aug 06, 2020: JanOne engages CATO SMS, a world-leading CRO, to assist in the development of JAN101 to treat COVID-19 vascular complications
Aug 04, 2020: JanOne changes interl drug candidate me from TV1001SR to JAN101
Jul 21, 2020: JanOne receives FDA authorization for transfer of Investigatiol New Drug (IND) application for its Sodium Nitrite tablets
Jul 20, 2020: Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..1)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..2)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, 2022